Compare · LITS vs VKTX

LITS vs VKTX

Side-by-side comparison of Lite Strategy Inc. (LITS) and Viking Therapeutics Inc. (VKTX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both LITS and VKTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • VKTX is the larger of the two at $3.30B, about 131.7x LITS ($25.0M).
  • LITS has been more active in the news (10 items in the past 4 weeks vs 7 for VKTX).
  • VKTX has more recent analyst coverage (24 ratings vs 0 for LITS).
MetricLITSVKTX
Company
Lite Strategy Inc.
Viking Therapeutics Inc.
Price
-
-
Market cap
$25.0M
$3.30B
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2003
2015
News (4w)
10
7
Recent ratings
0
24
VKTX

Viking Therapeutics Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Latest LITS

Latest VKTX